Curis
"CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 7, 2003--CURIS, Inc. (NASDAQ:CRIS - News) - The current online issue of The Proceedings of the National Academy of Sciences reports that CURIS scientists have identified a novel small molecule drug candidate, CUR-61414, for the treatment of basal cell carcinoma (BCC), a skin cancer and the most common form of all human cancers with approximately one million new cases every year in the United States. The report further states that CUR-61414 prevents the proliferation and selectively induces the death of the tumor cells, while not harming adjacent normal skin cells in two different models of BCC."
The oncology sector retains its attractiveness, sort of. The reaction to today's news release is perhaps somewhat overdone. Considering what was already known.
As a matter of fact Curis received FDA approval to start clinical trials with this compound already one and a half year ago. I don't know if they did start the trial or not, before they embraced the fact that the company in its previous set-up was travelling done a financial one-way street. The efforts were abandoned - the company saying that they had realised that the method of administration (i.e. injection) was perhaps not the most practical. Which seems reasonable.
Erik
Cambridge, MA September 5, 2001 - Curis, Inc. (NASDAQ: CRIS) today announced a Phase 1 Open-Label, Sequential Dose-Escalation Study of Intralesional Injection (inside the tumor itself) of Cur-61414 in Patients with Sporadic Basal Cell Carcinoma, the most common form of skin cancer. |
